Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI-2 substudy) - PubMed (original) (raw)
Randomized Controlled Trial
. 2005 Dec 1;96(11):1469-75.
doi: 10.1016/j.amjcard.2005.07.053. Epub 2005 Oct 11.
Affiliations
- PMID: 16310424
- DOI: 10.1016/j.amjcard.2005.07.053
Randomized Controlled Trial
Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI-2 substudy)
Mette M Madsen et al. Am J Cardiol. 2005.
Abstract
Little is known about the effect of diabetes mellitus on long-term clinical outcome after primary percutaneous coronary intervention (pPCI) compared with fibrinolysis in patients who have acute ST-elevation myocardial infarction. We analyzed 3-year clinical outcome in diabetic patients and nondiabetic patients who had been randomized to fibrinolysis or pPCI in the DANAMI-2 trial to compare long-term clinical outcome. The primary end point was a composite of death, clinical reinfarction, or disabling stroke. Median follow-up was 3.8 years. Among 1,572 consecutive patients who had ST-elevation myocardial infarction and were randomized to pPCI or fibrinolysis, 173 (11.0%) had diabetes mellitus; 60 of these patients received metformin treatment and were excluded. After 3 years no difference was found between diabetic patients who underwent pPCI versus fibrinolysis (combined event p=0.37, reinfarction p=0.06 in favor of fibrinolysis), whereas pPCI was superior to fibrinolysis in nondiabetic patients (combined event p=0.002, clinical reinfarction p<0.001). Three-year incidence of clinical reinfarction analyzed with Cox's regression showed that pPCI compared with fibrinolysis increased the relative risk of clinical reinfarction in diabetic patients (relative risk 2.57, 95% confidence interval 1.48 to 4.46, p <0.001) but decreased the risk in nondiabetic patients (relative risk 0.52, 95% confidence interval 0.36 to 0.74, p<0.001). In conclusion, from the DANAMI-2 trial we hypothesize that diabetes may abolish the beneficial effect of pPCI on long-term risk of clinical reinfarction.
Similar articles
- Long-term prognostic value of ST-segment resolution in patients treated with fibrinolysis or primary percutaneous coronary intervention results from the DANAMI-2 (DANish trial in acute myocardial infarction-2).
Sejersten M, Valeur N, Grande P, Nielsen TT, Clemmensen P; DANAMI-2 Investigators. Sejersten M, et al. J Am Coll Cardiol. 2009 Nov 3;54(19):1763-9. doi: 10.1016/j.jacc.2009.03.084. J Am Coll Cardiol. 2009. PMID: 19874989 Clinical Trial. - Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction-a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) substudy.
Maeng M, Nielsen PH, Busk M, Mortensen LS, Kristensen SD, Nielsen TT, Andersen HR; DANAMI-2 Investigators. Maeng M, et al. Am J Cardiol. 2010 Jun 1;105(11):1528-34. doi: 10.1016/j.amjcard.2010.01.005. Epub 2010 Apr 14. Am J Cardiol. 2010. PMID: 20494656 Clinical Trial. - Long-term prognosis in an ST-segment elevation myocardial infarction population treated with routine primary percutaneous coronary intervention: from clinical trial to real-life experience.
Pedersen S, Galatius S, Mogelvang R, Davidsen U, Galloe A, Abildstrom SZ, Abildgaard U, Hansen PR, Bech J, Iversen A, Jorgensen E, Kelbaek H, Saunamaki K, Madsen JK, Jensen JS. Pedersen S, et al. Circ Cardiovasc Interv. 2009 Oct;2(5):392-400. doi: 10.1161/CIRCINTERVENTIONS.108.845636. Epub 2009 Aug 18. Circ Cardiovasc Interv. 2009. PMID: 20031748 - [Thrombolysis or percutaneous coronary intervention in acute myocardial infarct].
Mihatov S. Mihatov S. Acta Med Croatica. 2004;58(2):139-42. Acta Med Croatica. 2004. PMID: 15208800 Review. Croatian. - Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials.
Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ; PCAT Collaborators. Percutaneous transluminal coronary angioplasty. Grines C, et al. Am Heart J. 2003 Jan;145(1):47-57. doi: 10.1067/mhj.2003.40. Am Heart J. 2003. PMID: 12514654 Review.
Cited by
- Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction.
Mortensen MB, Kulenovic I, Falk E. Mortensen MB, et al. Cardiovasc Diabetol. 2016 May 27;15:81. doi: 10.1186/s12933-016-0400-y. Cardiovasc Diabetol. 2016. PMID: 27229923 Free PMC article. - Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis.
Wisløff T, Selmer RM, Halvorsen S, Fretheim A, Norheim OF, Kristiansen IS. Wisløff T, et al. BMC Cardiovasc Disord. 2012 Apr 4;12:26. doi: 10.1186/1471-2261-12-26. BMC Cardiovasc Disord. 2012. PMID: 22475076 Free PMC article. - Fasting hyperglycemia increases in-hospital mortality risk in nondiabetic female patients with acute myocardial infarction: a retrospective study.
Luo G, Liu H, Luo S, Li F, Su M, Lu H. Luo G, et al. Int J Endocrinol. 2014;2014:745093. doi: 10.1155/2014/745093. Epub 2014 Jul 14. Int J Endocrinol. 2014. PMID: 25132854 Free PMC article. - A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes.
Cresci S, Huss JM, Beitelshees AL, Jones PG, Minton MR, Dorn GW, Kelly DP, Spertus JA, McLeod HL. Cresci S, et al. PLoS One. 2010 Sep 3;5(9):e12584. doi: 10.1371/journal.pone.0012584. PLoS One. 2010. PMID: 20838448 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical